Brief: Biogen Exercises Option With Denali To Develop And Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Denali Therapeutics

12/04/2023 20:24

April 12 (Reuters) - Biogen Inc  BIIB.O :
    * BIOGEN EXERCISES OPTION WITH DENALI TO DEVELOP AND
COMMERCIALIZE
ANTIBODY TRANSPORT VEHICLE PROGRAM TARGETING AMYLOID BETA
    * BIOGEN INC- FOLLOWING  EXERCISE OF OPTION, BIOGEN WILL
ASSUME
RESPONSIBILITY FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES AND
ASSOCIATED EXPENSES
    * BIOGEN INC - DENALI WILL BE ELIGIBLE TO RECEIVE POTENTIAL
DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS AND ROYALTIES
BASED ON FUTURE NET SALES
    * BIOGEN INC - DENALI WILL RECEIVE A ONE-TIME OPTION
EXERCISE
PAYMENT AND, SHOULD CERTAIN MILESTONES BE ACHIEVED


Further company coverage:  BIIB.O 

 ((Reuters.Briefs@thomsonreuters.com;))